Denali Therapeutics (DNLI) Competitors $22.95 -0.27 (-1.16%) (As of 10:27 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends DNLI vs. NBIX, TECH, PCVX, QGEN, EXEL, RGEN, RVMD, HALO, KRYS, and ACLXShould you be buying Denali Therapeutics stock or one of its competitors? The main competitors of Denali Therapeutics include Neurocrine Biosciences (NBIX), Bio-Techne (TECH), Vaxcyte (PCVX), Qiagen (QGEN), Exelixis (EXEL), Repligen (RGEN), Revolution Medicines (RVMD), Halozyme Therapeutics (HALO), Krystal Biotech (KRYS), and Arcellx (ACLX). These companies are all part of the "biological products, except diagnostic" industry. Denali Therapeutics vs. Neurocrine Biosciences Bio-Techne Vaxcyte Qiagen Exelixis Repligen Revolution Medicines Halozyme Therapeutics Krystal Biotech Arcellx Denali Therapeutics (NASDAQ:DNLI) and Neurocrine Biosciences (NASDAQ:NBIX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, community ranking, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment. Is DNLI or NBIX more profitable? Neurocrine Biosciences has a net margin of 17.21% compared to Denali Therapeutics' net margin of 0.00%. Neurocrine Biosciences' return on equity of 15.68% beat Denali Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Denali TherapeuticsN/A -32.94% -30.04% Neurocrine Biosciences 17.21%15.68%11.38% Do analysts prefer DNLI or NBIX? Denali Therapeutics currently has a consensus price target of $40.40, suggesting a potential upside of 73.99%. Neurocrine Biosciences has a consensus price target of $166.00, suggesting a potential upside of 21.44%. Given Denali Therapeutics' higher possible upside, analysts clearly believe Denali Therapeutics is more favorable than Neurocrine Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Denali Therapeutics 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.82Neurocrine Biosciences 0 Sell rating(s) 5 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 2.83 Which has stronger valuation & earnings, DNLI or NBIX? Neurocrine Biosciences has higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDenali Therapeutics$330.53M10.11-$145.22M-$2.76-8.41Neurocrine Biosciences$2.24B6.17$249.70M$3.7336.65 Does the MarketBeat Community favor DNLI or NBIX? Neurocrine Biosciences received 562 more outperform votes than Denali Therapeutics when rated by MarketBeat users. Likewise, 77.45% of users gave Neurocrine Biosciences an outperform vote while only 67.82% of users gave Denali Therapeutics an outperform vote. CompanyUnderperformOutperformDenali TherapeuticsOutperform Votes45167.82% Underperform Votes21432.18% Neurocrine BiosciencesOutperform Votes101377.45% Underperform Votes29522.55% Does the media refer more to DNLI or NBIX? In the previous week, Neurocrine Biosciences had 19 more articles in the media than Denali Therapeutics. MarketBeat recorded 28 mentions for Neurocrine Biosciences and 9 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.34 beat Neurocrine Biosciences' score of 0.97 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neurocrine Biosciences 14 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of DNLI or NBIX? 92.9% of Denali Therapeutics shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 7.9% of Denali Therapeutics shares are held by insiders. Comparatively, 4.3% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility & risk, DNLI or NBIX? Denali Therapeutics has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 0.34, indicating that its share price is 66% less volatile than the S&P 500. SummaryNeurocrine Biosciences beats Denali Therapeutics on 13 of the 19 factors compared between the two stocks. Ad ProsperityPubCould this be the hottest crypto discovery of all time?I want to let you in on what may be the hottest crypto discovery of all time… One that has NOTHING to do with creating a crypto wallet or touching ANY risky coin for that matter. Instead, it’s a way that could let regular folks like you and me target 10X the possible results you’d expect from buying Bitcoin … in just a fraction of the time It sounds nuts… trust me I know that… But just as I would hate for you to jump into any risky crypto asset… That’s exactly how I would hate for you to miss out on what could be a safer and better way to benefit from the crypto bull run of 2024. Which is why I’m giving you an opportunity to get all the details of this iconic crypto discovery with you for the first time ever… completely free…If you want in, Just Click Here Get Denali Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNLI vs. The Competition Export to ExcelMetricDenali TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.34B$2.98B$5.14B$9.31BDividend YieldN/A1.85%4.81%4.06%P/E Ratio-8.4146.22135.1917.53Price / Sales10.11440.311,232.15140.37Price / CashN/A182.1340.6537.95Price / Book3.133.924.884.92Net Income-$145.22M-$42.03M$118.97M$225.78M7 Day Performance-2.72%-3.37%15.41%-1.58%1 Month Performance-3.97%7.95%15.47%6.67%1 Year Performance6.61%21.00%34.58%22.48% Denali Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNLIDenali Therapeutics4.4833 of 5 stars$22.95-1.2%$40.40+76.0%+1.2%$3.30B$330.53M-8.32364Analyst UpgradePositive NewsNBIXNeurocrine Biosciences4.8855 of 5 stars$134.40+6.1%$165.00+22.8%+13.7%$13.61B$2.24B35.791,400Analyst ForecastPositive NewsTECHBio-Techne4.3175 of 5 stars$76.44+1.0%$82.00+7.3%-0.9%$12.15B$1.17B81.073,100Short Interest ↑Positive NewsPCVXVaxcyte1.8125 of 5 stars$90.59+3.3%$147.50+62.8%+48.4%$11.29BN/A-19.07160QGENQiagen4.227 of 5 stars$45.41+0.0%$51.15+12.6%+3.6%$10.36B$1.97B117.035,967EXELExelixis4.5611 of 5 stars$36.02+2.8%$31.47-12.6%+48.2%$10.29B$2.08B22.461,310Analyst DowngradeShort Interest ↑RGENRepligen3.7688 of 5 stars$159.52+2.0%$190.25+19.3%-12.7%$8.94B$639.92M-422.731,783Analyst ForecastAnalyst RevisionPositive NewsRVMDRevolution Medicines4.6668 of 5 stars$44.68-0.7%$63.67+42.5%+69.6%$7.52B$11.58M-12.54443Positive NewsHALOHalozyme Therapeutics4.9931 of 5 stars$48.39+0.8%$61.11+26.3%+24.6%$6.16B$947.36M15.98390Analyst ForecastPositive NewsKRYSKrystal Biotech4.3121 of 5 stars$171.57+4.8%$206.67+20.5%+46.0%$4.93B$50.70M92.45229Analyst ForecastACLXArcellx3.2007 of 5 stars$85.12+1.6%$105.93+24.4%+60.5%$4.60B$155.82M-118.03130 Related Companies and Tools Related Companies Neurocrine Biosciences Competitors Bio-Techne Competitors Vaxcyte Competitors Qiagen Competitors Exelixis Competitors Repligen Competitors Revolution Medicines Competitors Halozyme Therapeutics Competitors Krystal Biotech Competitors Arcellx Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DNLI) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Denali Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DNLI Stock Alerts